{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:30:27Z","timestamp":1793424627974,"version":"4.5.0"},"reference-count":117,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40257-025-00924-0","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T04:30:51Z","timestamp":1738297851000},"page":"379-393","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Morbilliform Eruptions: Differentiating Low-Risk Drug Eruptions, Severe Cutaneous Adverse Reactions, Viral Eruptions, and Acute Graft-Versus-Host Disease"],"prefix":"10.1007","volume":"26","author":[{"given":"Allison","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Madigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Korman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Shearer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Dulmage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tejesh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Milani-Nejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristopher","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8079-0011","authenticated-orcid":false,"given":"Benjamin","family":"Kaffenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,31]]},"reference":[{"issue":"8","key":"924_CR1","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1111\/ijd.16575","volume":"62","author":"C Pettit","year":"2023","unstructured":"Pettit C, Trinidad J, Chung C, Patterson A, Kaffenberger BH. Hospital triage and skin disease: hospital outcomes are differentially associated with cutaneous morphology. Int J Dermatol. 2023;62(8):1034\u20139. https:\/\/doi.org\/10.1111\/ijd.16575.","journal-title":"Int J Dermatol"},{"issue":"10","key":"924_CR2","doi-asserted-by":"publisher","first-page":"e547","DOI":"10.1111\/ijd.13327","volume":"55","author":"F Galimberti","year":"2016","unstructured":"Galimberti F, Guren L, Fernandez AP, Sood A. Dermatology consultations significantly contribute quality to care of hospitalized patients: a prospective study of dermatology inpatient consults at a tertiary care center. Int J Dermatol. 2016;55(10):e547\u201351. https:\/\/doi.org\/10.1111\/ijd.13327.","journal-title":"Int J Dermatol"},{"issue":"3","key":"924_CR3","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.jaad.2016.08.034","volume":"76","author":"AM Korman","year":"2017","unstructured":"Korman AM, Alikhan A, Kaffenberger BH. Viral exanthems: an update on laboratory testing of the adult patient. J Am Acad Dermatol. 2017;76(3):538\u201350. https:\/\/doi.org\/10.1016\/j.jaad.2016.08.034.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"924_CR4","doi-asserted-by":"publisher","first-page":"e319","DOI":"10.1111\/ijd.16249","volume":"62","author":"M Gallardo","year":"2023","unstructured":"Gallardo M, Gilkey T, Korman A, Chung C, Trinidad J, Kaffenberger BH. Drug eruptions are associated with increased length of stay in hospitalized patients with sepsis. Int J Dermatol. 2023;62(5):e319\u201320. https:\/\/doi.org\/10.1111\/ijd.16249.","journal-title":"Int J Dermatol"},{"key":"924_CR5","doi-asserted-by":"crossref","unstructured":"Yan A et al. Impact of morbilliform drug eruptions on health-related quality of life: a qualitative analysis. The Ohio State University Wexner Medical Center, 2024.","DOI":"10.1093\/bjd\/ljaf072"},{"issue":"2","key":"924_CR6","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.jaci.2011.09.028","volume":"129","author":"J Sastre","year":"2012","unstructured":"Sastre J, Manso L, Sanchez-Garc\u00eda S, Fern\u00e1ndez-Nieto M. Medical and economic impact of misdiagnosis of drug hypersensitivity in hospitalized patients. J Allergy Clin Immunol. 2012;129(2):566\u20137. https:\/\/doi.org\/10.1016\/j.jaci.2011.09.028.","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"924_CR7","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.arcmed.2006.03.010","volume":"37","author":"A Hern\u00e1ndez-Salazar","year":"2006","unstructured":"Hern\u00e1ndez-Salazar A, Rosales SP, Rangel-Frausto S, Criollo E, Archer-Dubon C, Orozco-Topete R. Epidemiology of adverse cutaneous drug reactions. A prospective study in hospitalized patients. Arch Med Res. 2006;37(7):899\u2013902. https:\/\/doi.org\/10.1016\/j.arcmed.2006.03.010.","journal-title":"Arch Med Res"},{"key":"924_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jdin.2020.12.004","volume":"3","author":"DAQ Oh","year":"2021","unstructured":"Oh DAQ, Yeo YW, Choo KJL, Pang SM, Oh CC, Lee HY. Acute generalized exanthematous pustulosis: epidemiology, clinical course, and treatment outcomes of patients treated in an Asian academic medical center. JAAD Int. 2021;3:1\u20136. https:\/\/doi.org\/10.1016\/j.jdin.2020.12.004.","journal-title":"JAAD Int"},{"issue":"3","key":"924_CR9","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7241\/ourd.20233.6","volume":"14","author":"Z Mehsas","year":"2023","unstructured":"Mehsas Z, et al. DRESS syndrome: a descriptive series of 63 cases. Our Dermatol Online. 2023;14(3):268\u201373.","journal-title":"Our Dermatol Online"},{"key":"924_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jdin.2023.06.014","volume":"13","author":"P Wasuwanich","year":"2023","unstructured":"Wasuwanich P, So JM, Chakrala TS, Chen J, Motaparthi K. Epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States and factors predictive of outcome. JAAD Int. 2023;13:17\u201325. https:\/\/doi.org\/10.1016\/j.jdin.2023.06.014.","journal-title":"JAAD Int"},{"issue":"6","key":"924_CR11","first-page":"765","volume":"137","author":"M Bigby","year":"2001","unstructured":"Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol. 2001;137(6):765\u201370.","journal-title":"Arch Dermatol"},{"issue":"4","key":"924_CR12","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/j.1398-9995.1997.tb01017.x","volume":"52","author":"T Hunziker","year":"1997","unstructured":"Hunziker T, K\u00fcnzi UP, Braunschweig S, Zehnder D, Hoign\u00e9 R. Comprehensive hospital drug monitoring (CHDM): adverse skin reactions, a 20-year survey. Allergy. 1997;52(4):388\u201393. https:\/\/doi.org\/10.1111\/j.1398-9995.1997.tb01017.x.","journal-title":"Allergy"},{"issue":"10","key":"924_CR13","first-page":"767","volume":"51","author":"HY Lee","year":"2010","unstructured":"Lee HY, Tay LK, Thirumoorthy T, Pang SM. Cutaneous adverse drug reactions in hospitalised patients. Singapore Med J. 2010;51(10):767\u201374.","journal-title":"Singapore Med J"},{"issue":"6","key":"924_CR14","first-page":"59","volume":"15","author":"T Gilkey","year":"2022","unstructured":"Gilkey T, Trinidad J, Kovalchin C, Minta A, Rosenbach M, Kaffenberger BH. Defining drugs that are high-risk associations for drug reactions within the hospital setting. J Clin Aesthet Dermatol. 2022;15(6):59\u201364.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"11","key":"924_CR15","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1073\/pnas.0409500102","volume":"102","author":"SI Hung","year":"2005","unstructured":"Hung SI, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA. 2005;102(11):4134\u20139. https:\/\/doi.org\/10.1073\/pnas.0409500102.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"924_CR16","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1001\/jamadermatol.2013.4114","volume":"149","author":"W Tangamornsuksan","year":"2013","unstructured":"Tangamornsuksan W, Chaiyakunapruk N, Somkrua R, Lohitnavy M, Tassaneeyakul W. Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol. 2013;149(9):1025\u201332. https:\/\/doi.org\/10.1001\/jamadermatol.2013.4114.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"924_CR17","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1055\/s-0034-1375684","volume":"65","author":"X Li","year":"2015","unstructured":"Li X, et al. HLA-B*1502 increases the risk of phenytoin or lamotrigine induced Stevens-Johnson syndrome\/toxic epidermal necrolysis: evidence from a meta-analysis of nine case-control studies. Drug Res (Stuttg). 2015;65(2):107\u201311. https:\/\/doi.org\/10.1055\/s-0034-1375684.","journal-title":"Drug Res (Stuttg)"},{"issue":"7","key":"924_CR18","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/j.jid.2018.02.004","volume":"138","author":"WT Chen","year":"2018","unstructured":"Chen WT, et al. The function of HLA-B*13:01 involved in the pathomechanism of dapsone-induced severe cutaneous adverse reactions. J Invest Dermatol. 2018;138(7):1546\u201354. https:\/\/doi.org\/10.1016\/j.jid.2018.02.004.","journal-title":"J Invest Dermatol"},{"issue":"8","key":"924_CR19","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/s0895-4356(98)00041-9","volume":"51","author":"PD van der Linden","year":"1998","unstructured":"van der Linden PD, van der Lei J, Vlug AE, Stricker BH. Skin reactions to antibacterial agents in general practice. J Clin Epidemiol. 1998;51(8):703\u20138. https:\/\/doi.org\/10.1016\/s0895-4356(98)00041-9.","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"924_CR20","first-page":"720","volume":"19","author":"F Mokhtari","year":"2014","unstructured":"Mokhtari F, Nikyar Z, Naeini BA, Esfahani AA, Rahmani S. Adverse cutaneous drug reactions: eight year assessment in hospitalized patients. J Res Med Sci. 2014;19(8):720\u20135.","journal-title":"J Res Med Sci"},{"issue":"6","key":"924_CR21","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/ijd.14703","volume":"59","author":"AJ Krispinsky","year":"2020","unstructured":"Krispinsky AJ, Shedlofsky LB, Kaffenberger BH. The frequency of low-risk morbilliform drug eruptions observed in patients treated with different classes of antibiotics. Int J Dermatol. 2020;59(6):647\u201355. https:\/\/doi.org\/10.1111\/ijd.14703.","journal-title":"Int J Dermatol"},{"issue":"11","key":"924_CR22","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/pds.4067","volume":"25","author":"A Stewart","year":"2016","unstructured":"Stewart A, Lehloenya R, Boulle A, de Waal R, Maartens G, Cohen K. Severe antiretroviral-associated skin reactions in South African patients: a case series and case-control analysis. Pharmacoepidemiol Drug Saf. 2016;25(11):1313\u20139. https:\/\/doi.org\/10.1002\/pds.4067.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"12","key":"924_CR23","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1111\/cup.13047","volume":"44","author":"S Singh","year":"2017","unstructured":"Singh S, et al. Assessment of histopathological features of maculopapular viral exanthem and drug-induced exanthem. J Cutan Pathol. 2017;44(12):1038\u201348. https:\/\/doi.org\/10.1111\/cup.13047.","journal-title":"J Cutan Pathol"},{"issue":"12","key":"924_CR24","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1111\/cup.14306","volume":"49","author":"M Ernst","year":"2022","unstructured":"Ernst M, Lundgren M, Evans MD, Miller D, Giubellino A. The mixed spongiotic and interface reaction pattern: a study of clinical and histopathologic findings. J Cutan Pathol. 2022;49(12):1051\u20139. https:\/\/doi.org\/10.1111\/cup.14306.","journal-title":"J Cutan Pathol"},{"issue":"5","key":"924_CR25","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.jaad.2013.06.022","volume":"69","author":"CS Seitz","year":"2013","unstructured":"Seitz CS, Rose C, Kerstan A, Trautmann A. Drug-induced exanthems: correlation of allergy testing with histologic diagnosis. J Am Acad Dermatol. 2013;69(5):721\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2013.06.022.","journal-title":"J Am Acad Dermatol"},{"issue":"26","key":"924_CR26","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1056\/NEJMcp1104080","volume":"366","author":"RS Stern","year":"2012","unstructured":"Stern RS. Clinical practice. Exanthematous drug eruptions. N Engl J Med. 2012;366(26):2492\u2013501. https:\/\/doi.org\/10.1056\/NEJMcp1104080.","journal-title":"N Engl J Med"},{"issue":"1","key":"924_CR27","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/clpt.2009.252","volume":"88","author":"B Sassolas","year":"2010","unstructured":"Sassolas B, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther. 2010;88(1):60\u20138. https:\/\/doi.org\/10.1038\/clpt.2009.252.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"924_CR28","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jaad.2020.09.024","volume":"87","author":"MA Hadavand","year":"2022","unstructured":"Hadavand MA, Kaffenberger B, Cartron AM, Trinidad JCL. Clinical presentation and management of atypical and recalcitrant acute generalized exanthematous pustulosis. J Am Acad Dermatol. 2022;87(3):632\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2020.09.024.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"924_CR29","doi-asserted-by":"publisher","first-page":"e776","DOI":"10.1111\/jdv.18940","volume":"37","author":"M Weiss","year":"2023","unstructured":"Weiss M, et al. Acute generalized exanthematous pustulosis: clinico-biological profile and inducing drugs in 83 patients. J Eur Acad Dermatol Venereol. 2023;37(6):e776\u20138. https:\/\/doi.org\/10.1111\/jdv.18940.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"924_CR30","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.jaad.2015.07.017","volume":"73","author":"J Szatkowski","year":"2015","unstructured":"Szatkowski J, Schwartz RA. Acute generalized exanthematous pustulosis (AGEP): a review and update. J Am Acad Dermatol. 2015;73(5):843\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2015.07.017.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"924_CR31","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1001\/jamadermatol.2021.5390","volume":"158","author":"A Creadore","year":"2022","unstructured":"Creadore A, et al. Clinical characteristics, disease course, and outcomes of patients with acute generalized exanthematous pustulosis in the US. JAMA Dermatol. 2022;158(2):176\u201383. https:\/\/doi.org\/10.1001\/jamadermatol.2021.5390.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"924_CR32","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1034\/j.1600-0560.2001.028003113.x","volume":"28","author":"A Sidoroff","year":"2001","unstructured":"Sidoroff A, Halevy S, Bavinck JN, Vaillant L, Roujeau JC. Acute generalized exanthematous pustulosis (AGEP)\u2014a clinical reaction pattern. J Cutan Pathol. 2001;28(3):113\u20139. https:\/\/doi.org\/10.1034\/j.1600-0560.2001.028003113.x.","journal-title":"J Cutan Pathol"},{"key":"924_CR33","doi-asserted-by":"crossref","unstructured":"Awethe Z et al. Optimizing the EuroSCAR criteria for acute generalized exanthematous pustulosis (AGEP): a streamlined diagnostic model. The Ohio State University Wexner Medical Center. 2024.","DOI":"10.1016\/j.jaad.2024.07.1418"},{"key":"924_CR34","unstructured":"Awethe Z et al. Validation of the EuroSCAR criteria for acute generalized exanthematous pustulosis: a retrospective cohort study. The Ohio State University Wexner Medical Center. 2024."},{"key":"924_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2021.113036","volume":"493","author":"B Sachs","year":"2021","unstructured":"Sachs B, Fatangare A, Sickmann A, Gl\u00e4ssner A. Lymphocyte transformation test: history and current approaches. J Immunol Methods. 2021;493: 113036. https:\/\/doi.org\/10.1016\/j.jim.2021.113036.","journal-title":"J Immunol Methods"},{"issue":"1","key":"924_CR36","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13223-022-00729-4","volume":"18","author":"C Weir","year":"2022","unstructured":"Weir C, Li J, Fulton R, Fernando SL. Development and initial validation of a modified lymphocyte transformation test (LTT) assay in patients with DRESS and AGEP. Allergy Asthma Clin Immunol. 2022;18(1):90. https:\/\/doi.org\/10.1186\/s13223-022-00729-4.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"3","key":"924_CR37","first-page":"210","volume":"3","author":"B Prange","year":"2005","unstructured":"Prange B, Marini A, Kalke A, Hodzic-Avdagic N, Ruzicka T, Hengge UR. [Acute localized exanthematous pustulosis (ALEP)] (in German). J Dtsch Dermatol Ges. 2005;3(3):210\u20132.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"5","key":"924_CR38","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15087","volume":"34","author":"I Safa","year":"2021","unstructured":"Safa I, et al. Acute localized exanthematous pustulosis: clinical features, pathophysiology, and therapy. Dermatol Ther. 2021;34(5): e15087. https:\/\/doi.org\/10.1111\/dth.15087.","journal-title":"Dermatol Ther"},{"issue":"7","key":"924_CR39","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.jdcr.2018.03.017","volume":"4","author":"Z Hopkins","year":"2018","unstructured":"Hopkins Z, Frigerio A, Clarke JT. Acute localized exanthematous pustulosis (ALEP) caused by lamotrigine. JAAD Case Rep. 2018;4(7):645\u20137. https:\/\/doi.org\/10.1016\/j.jdcr.2018.03.017.","journal-title":"JAAD Case Rep"},{"issue":"7","key":"924_CR40","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1001\/jamadermatol.2024.1082","volume":"160","author":"E Hansen","year":"2024","unstructured":"Hansen E, et al. Drug reaction with eosinophilia and systemic symptoms with pustulosis. JAMA Dermatol. 2024;160(7):777\u20139. https:\/\/doi.org\/10.1001\/jamadermatol.2024.1082.","journal-title":"JAMA Dermatol"},{"key":"924_CR41","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/1750-1172-7-72","volume":"7","author":"S Bouvresse","year":"2012","unstructured":"Bouvresse S, et al. Toxic epidermal necrolysis, DRESS, AGEP: do overlap cases exist? Orphanet J Rare Dis. 2012;7:72. https:\/\/doi.org\/10.1186\/1750-1172-7-72.","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"924_CR42","doi-asserted-by":"publisher","first-page":"e739","DOI":"10.1111\/jdv.18270","volume":"36","author":"TW Gilkey","year":"2022","unstructured":"Gilkey TW, et al. Oblique earlobe crease as a novel physical examination finding in drug reaction with eosinophilia and systemic symptoms: a retrospective study. J Eur Acad Dermatol Venereol. 2022;36(9):e739\u201340. https:\/\/doi.org\/10.1111\/jdv.18270.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"924_CR43","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.jaad.2023.02.072","volume":"90","author":"BM Wei","year":"2024","unstructured":"Wei BM, et al. Drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms. Part I. Epidemiology, pathogenesis, clinicopathological features, and prognosis. J Am Acad Dermatol. 2024;90(5):885\u2013908. https:\/\/doi.org\/10.1016\/j.jaad.2023.02.072.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"924_CR44","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.jaad.2023.02.073","volume":"90","author":"BM Wei","year":"2024","unstructured":"Wei BM, et al. Drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms. Part II diagnosis and management. J Am Acad Dermatol. 2024;90(5):911\u201326. https:\/\/doi.org\/10.1016\/j.jaad.2023.02.073.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"924_CR45","doi-asserted-by":"publisher","first-page":"e310","DOI":"10.1111\/jdv.17838","volume":"36","author":"S Takei","year":"2022","unstructured":"Takei S, et al. Purpura as an indicator of severity in drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms: evidence from a 49-case series. J Eur Acad Dermatol Venereol. 2022;36(4):e310\u20133. https:\/\/doi.org\/10.1111\/jdv.17838.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"924_CR46","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1111\/j.1468-3083.2008.02585.x","volume":"22","author":"CC Chiou","year":"2008","unstructured":"Chiou CC, et al. Clinicopathological features and prognosis of drug rash with eosinophilia and systemic symptoms: a study of 30 cases in Taiwan. J Eur Acad Dermatol Venereol. 2008;22(9):1044\u20139. https:\/\/doi.org\/10.1111\/j.1468-3083.2008.02585.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"924_CR47","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1111\/ijd.13667","volume":"56","author":"JY Lee","year":"2017","unstructured":"Lee JY, Lee SY, Hahm JE, Ha JW, Kim CW, Kim SS. Clinical features of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a study of 25 patients in Korea. Int J Dermatol. 2017;56(9):944\u201351. https:\/\/doi.org\/10.1111\/ijd.13667.","journal-title":"Int J Dermatol"},{"issue":"8","key":"924_CR48","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1016\/j.jaip.2019.05.047","volume":"7","author":"HJ Park","year":"2019","unstructured":"Park HJ, et al. Unique clinical characteristics and prognosis of allopurinol-induced severe cutaneous adverse reactions. J Allergy Clin Immunol Pract. 2019;7(8):2739-2749.e3. https:\/\/doi.org\/10.1016\/j.jaip.2019.05.047.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"924_CR49","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.jaad.2019.09.036","volume":"82","author":"A Soria","year":"2020","unstructured":"Soria A, Bernier C, Veyrac G, Barbaud A, Puymirat E, Milpied B. Drug reaction with eosinophilia and systemic symptoms may occur within 2 weeks of drug exposure: a retrospective study. J Am Acad Dermatol. 2020;82(3):606\u201311. https:\/\/doi.org\/10.1016\/j.jaad.2019.09.036.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"924_CR50","doi-asserted-by":"publisher","first-page":"e342","DOI":"10.1111\/ijd.16317","volume":"62","author":"C Park","year":"2023","unstructured":"Park C, Kaffenberger BH, Trinidad JCL, Korman AM. Diagnostic methods for severe cutaneous adverse drug reactions by inpatient dermatologists. Int J Dermatol. 2023;62(6):e342\u20134. https:\/\/doi.org\/10.1111\/ijd.16317.","journal-title":"Int J Dermatol"},{"issue":"3","key":"924_CR51","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.alit.2019.03.006","volume":"68","author":"T Shiohara","year":"2019","unstructured":"Shiohara T, Mizukawa Y. Drug-induced hypersensitivity syndrome (DiHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS): an update in 2019. Allergol Int. 2019;68(3):301\u20138. https:\/\/doi.org\/10.1016\/j.alit.2019.03.006.","journal-title":"Allergol Int"},{"issue":"5","key":"924_CR52","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.jaad.2020.09.021","volume":"88","author":"N Milani-Nejad","year":"2023","unstructured":"Milani-Nejad N, Trinidad J, Kaffenberger BH. Acute kidney injury in vancomycin-induced drug reaction with eosinophilia and systemic symptoms: a case-control study. J Am Acad Dermatol. 2023;88(5):1121\u20133. https:\/\/doi.org\/10.1016\/j.jaad.2020.09.021.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"924_CR53","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.dsi.2013.09.006","volume":"31","author":"Y-C Chen","year":"2013","unstructured":"Chen Y-C, Cho Y-T, Chang C-Y, Chu C-Y. Drug reaction with eosinophilia and systemic symptoms: a drug-induced hypersensitivity syndrome with variable clinical features. Dermatol Sin. 2013;31(4):196\u2013204.","journal-title":"Dermatol Sin"},{"issue":"5","key":"924_CR54","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1111\/bjd.12501","volume":"169","author":"SH Kardaun","year":"2013","unstructured":"Kardaun SH, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013;169(5):1071\u201380. https:\/\/doi.org\/10.1111\/bjd.12501.","journal-title":"Br J Dermatol"},{"issue":"9","key":"924_CR55","doi-asserted-by":"publisher","first-page":"e478","DOI":"10.1111\/ijd.16642","volume":"62","author":"E Hansen","year":"2023","unstructured":"Hansen E, Gallardo M, Kaffenberger BH, Fisher K, Korman AM. Older DRESS patients are more likely to have cytopenias: a retrospective cohort study. Int J Dermatol. 2023;62(9):e478\u201380. https:\/\/doi.org\/10.1111\/ijd.16642.","journal-title":"Int J Dermatol"},{"issue":"4","key":"924_CR56","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/s1085-5629(96)80038-1","volume":"15","author":"H Bocquet","year":"1996","unstructured":"Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: DRESS). Semin Cutan Med Surg. 1996;15(4):250\u20137. https:\/\/doi.org\/10.1016\/s1085-5629(96)80038-1.","journal-title":"Semin Cutan Med Surg"},{"issue":"3","key":"924_CR57","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/j.1365-2133.2006.07704.x","volume":"156","author":"SH Kardaun","year":"2007","unstructured":"Kardaun SH, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol. 2007;156(3):609\u201311. https:\/\/doi.org\/10.1111\/j.1365-2133.2006.07704.x.","journal-title":"Br J Dermatol"},{"issue":"5","key":"924_CR58","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/j.1365-2133.2007.07807.x","volume":"156","author":"T Shiohara","year":"2007","unstructured":"Shiohara T, Iijima M, Ikezawa Z, Hashimoto K. The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations. Br J Dermatol. 2007;156(5):1083\u20134. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.07807.x.","journal-title":"Br J Dermatol"},{"issue":"7","key":"924_CR59","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1001\/archderm.134.7.874","volume":"134","author":"RD Sontheimer","year":"1998","unstructured":"Sontheimer RD, Houpt KR. DIDMOHS: a proposed consensus nomenclature for the drug-induced delayed multiorgan hypersensitivity syndrome. Arch Dermatol. 1998;134(7):874\u20136. https:\/\/doi.org\/10.1001\/archderm.134.7.874.","journal-title":"Arch Dermatol"},{"issue":"2","key":"924_CR60","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jaad.2009.08.050","volume":"63","author":"CC Ang","year":"2010","unstructured":"Ang CC, Wang YS, Yoosuff EL, Tay YK. Retrospective analysis of drug-induced hypersensitivity syndrome: a study of 27 patients. J Am Acad Dermatol. 2010;63(2):219\u201327. https:\/\/doi.org\/10.1016\/j.jaad.2009.08.050.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"924_CR61","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.1365-2133.2006.07238.x","volume":"155","author":"Y Kano","year":"2006","unstructured":"Kano Y, Hiraharas K, Sakuma K, Shiohara T. Several herpesviruses can reactivate in a severe drug-induced multiorgan reaction in the same sequential order as in graft-versus-host disease. Br J Dermatol. 2006;155(2):301\u20136. https:\/\/doi.org\/10.1111\/j.1365-2133.2006.07238.x.","journal-title":"Br J Dermatol"},{"issue":"1","key":"924_CR62","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.jaad.2020.03.095","volume":"83","author":"N Milani-Nejad","year":"2020","unstructured":"Milani-Nejad N, Trinidad J, Kaffenberger BH. Viral reactivation in hospitalized patients with drug reaction with eosinophilia and systemic symptoms: A retrospective study from a tertiary medical center in the United States. J Am Acad Dermatol. 2020;83(1):278\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2020.03.095.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"924_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.05.022","volume":"83","author":"N Milani-Nejad","year":"2020","unstructured":"Milani-Nejad N, Trinidad J, Kaffenberger BH. Reply to: \u201cComment on Viral reactivation in hospitalized DRESS patients: a retrospective study from a tertiary medical center in the United States.\u201d J Am Acad Dermatol. 2020;83(3): e211. https:\/\/doi.org\/10.1016\/j.jaad.2020.05.022.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"924_CR64","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1001\/jamadermatol.2023.4450","volume":"160","author":"MC Br\u00fcggen","year":"2024","unstructured":"Br\u00fcggen MC, et al. Management of adult patients with drug reaction with eosinophilia and systemic symptoms: a Delphi-based international consensus. JAMA Dermatol. 2024;160(1):37\u201344. https:\/\/doi.org\/10.1001\/jamadermatol.2023.4450.","journal-title":"JAMA Dermatol"},{"key":"924_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.06.081","author":"E Hansen","year":"2024","unstructured":"Hansen E, et al. Risk assessment of drugs associated with DRESS syndrome based on publication frequency: a systematic review. J Am Acad Dermatol. 2024. https:\/\/doi.org\/10.1016\/j.jaad.2024.06.081.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"924_CR66","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.jaad.2018.08.052","volume":"80","author":"Y Mizukawa","year":"2019","unstructured":"Mizukawa Y, Hirahara K, Kano Y, Shiohara T. Drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms severity score: a useful tool for assessing disease severity and predicting fatal cytomegalovirus disease. J Am Acad Dermatol. 2019;80(3):670-678.e2. https:\/\/doi.org\/10.1016\/j.jaad.2018.08.052.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"924_CR67","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1016\/j.jaip.2023.06.065","volume":"11","author":"Y Mizukawa","year":"2023","unstructured":"Mizukawa Y, et al. Drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms: predictive score and outcomes. J Allergy Clin Immunol Pract. 2023;11(10):3169-3178.e7. https:\/\/doi.org\/10.1016\/j.jaip.2023.06.065.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"924_CR68","first-page":"E6","volume":"103","author":"JR Dowling","year":"2019","unstructured":"Dowling JR, Anderson KL, Huang WW. Asboe-Hansen sign in toxic epidermal necrolysis. Cutis. 2019;103(4):E6\u20138.","journal-title":"Cutis"},{"issue":"6","key":"924_CR69","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1001\/jamadermatol.2021.1136","volume":"157","author":"M Hoffman","year":"2021","unstructured":"Hoffman M, et al. Long-term physical and psychological outcomes of Stevens-Johnson syndrome\/toxic epidermal necrolysis. JAMA Dermatol. 2021;157(6):712\u20135. https:\/\/doi.org\/10.1001\/jamadermatol.2021.1136.","journal-title":"JAMA Dermatol"},{"issue":"10","key":"924_CR70","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1001\/jamadermatol.2022.3011","volume":"158","author":"LL Wang","year":"2022","unstructured":"Wang LL, Noe MH, Micheletti RG. Prevalence of leukopenia and associated outcomes in patients with Stevens-Johnson syndrome\/toxic epidermal necrolysis. JAMA Dermatol. 2022;158(10):1212\u20134. https:\/\/doi.org\/10.1001\/jamadermatol.2022.3011.","journal-title":"JAMA Dermatol"},{"key":"924_CR71","doi-asserted-by":"publisher","unstructured":"Noe MH, Micheletti RG, Mostaghimi A, S. o. D. H. S. T. S. Group. Timing of mucocutaneous symptoms and medication discontinuation in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States. J Am Acad Dermatol. 2019;81(6):1410\u20131412. https:\/\/doi.org\/10.1016\/j.jaad.2019.05.020.","DOI":"10.1016\/j.jaad.2019.05.020"},{"issue":"2","key":"924_CR72","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","volume":"115","author":"S Bastuji-Garin","year":"2000","unstructured":"Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115(2):149\u201353. https:\/\/doi.org\/10.1046\/j.1523-1747.2000.00061.x.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"924_CR73","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.jaad.2019.05.061","volume":"81","author":"A Weinkle","year":"2019","unstructured":"Weinkle A, et al. Distinguishing Stevens-Johnson syndrome\/toxic epidermal necrolysis from clinical mimickers during inpatient dermatologic consultation\u2014a retrospective chart review. J Am Acad Dermatol. 2019;81(3):749\u201357. https:\/\/doi.org\/10.1016\/j.jaad.2019.05.061.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"924_CR74","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/j.1346-8138.2009.00746.x","volume":"37","author":"H Hosaka","year":"2010","unstructured":"Hosaka H, Ohtoshi S, Nakada T, Iijima M. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis: frozen-section diagnosis. J Dermatol. 2010;37(5):407\u201312. https:\/\/doi.org\/10.1111\/j.1346-8138.2009.00746.x.","journal-title":"J Dermatol"},{"issue":"4","key":"924_CR75","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1001\/jamadermatol.2018.5605","volume":"155","author":"MH Noe","year":"2019","unstructured":"Noe MH, et al. Development and validation of a risk prediction model for in-hospital mortality among patients with Stevens-Johnson syndrome\/toxic epidermal necrolysis-ABCD-10. JAMA Dermatol. 2019;155(4):448\u201354. https:\/\/doi.org\/10.1001\/jamadermatol.2018.5605.","journal-title":"JAMA Dermatol"},{"issue":"10","key":"924_CR76","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1016\/j.jaip.2023.07.001","volume":"11","author":"N Hama","year":"2023","unstructured":"Hama N, et al. Development and validation of a novel score to predict mortality in Stevens-Johnson syndrome and toxic epidermal necrolysis: CRISTEN. J Allergy Clin Immunol Pract. 2023;11(10):3161-3168.e2. https:\/\/doi.org\/10.1016\/j.jaip.2023.07.001.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7","key":"924_CR77","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1007\/s00403-024-03062-5","volume":"316","author":"K Libson","year":"2024","unstructured":"Libson K, Mehta N, Kirven R, Korman AM, Kaffenberger BH. Outcome measurements in epidermal necrolysis: a systematic review. Arch Dermatol Res. 2024;316(7):392. https:\/\/doi.org\/10.1007\/s00403-024-03062-5.","journal-title":"Arch Dermatol Res"},{"key":"924_CR78","doi-asserted-by":"publisher","first-page":"883121","DOI":"10.3389\/fmed.2022.883121","volume":"9","author":"AS Dobry","year":"2022","unstructured":"Dobry AS, Himed S, Waters M, Kaffenberger BH. Scoring assessments in Stevens-Johnson syndrome and toxic epidermal necrolysis. Front Med (Lausanne). 2022;9:883121. https:\/\/doi.org\/10.3389\/fmed.2022.883121.","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"924_CR79","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239\u201345. https:\/\/doi.org\/10.1038\/clpt.1981.154.","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"924_CR80","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1001\/jamadermatol.2023.1693","volume":"159","author":"DJ Li","year":"2023","unstructured":"Li DJ, Velasquez GA, Romar GA, Schunkert EM, Foreman RK, Divito SJ. Assessment of need for improved identification of a culprit drug in Stevens-Johnson syndrome\/toxic epidermal necrolysis. JAMA Dermatol. 2023;159(8):830\u20136. https:\/\/doi.org\/10.1001\/jamadermatol.2023.1693.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"924_CR81","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.therap.2020.02.022","volume":"75","author":"K Bihan","year":"2020","unstructured":"Bihan K, Lebrun-Vignes B, Funck-Brentano C, Salem JE. Uses of pharmacovigilance databases: an overview. Therapie. 2020;75(6):591\u20138. https:\/\/doi.org\/10.1016\/j.therap.2020.02.022.","journal-title":"Therapie"},{"issue":"11","key":"924_CR82","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1016\/j.jaip.2023.08.009","volume":"11","author":"F Bassir","year":"2023","unstructured":"Bassir F, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): clinical presentation and outcomes in people of color. J Allergy Clin Immunol Pract. 2023;11(11):3537\u201340. https:\/\/doi.org\/10.1016\/j.jaip.2023.08.009.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"924_CR83","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jaad.2009.05.046","volume":"62","author":"KK Shaughnessy","year":"2010","unstructured":"Shaughnessy KK, Bouchard SM, Mohr MR, Herre JM, Salkey KS. Minocycline-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome with persistent myocarditis. J Am Acad Dermatol. 2010;62(2):315\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2009.05.046.","journal-title":"J Am Acad Dermatol"},{"key":"924_CR84","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.3390\/ph14111077","volume":"14","author":"C Kloypan","year":"2021","unstructured":"Kloypan C, Koomdee N, Satapornpong P, Tempark T, Biswas M, Sukasem C. A comprehensive review of HLA and severe cutaneous adverse drug reactions: implication for clinical pharmacogenomics and precision medicine. Pharmaceuticals. 2021;14:1077.","journal-title":"Pharmaceuticals"},{"issue":"1","key":"924_CR85","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200101","volume":"13","author":"WP Bensken","year":"2023","unstructured":"Bensken WP, et al. Racial and ethnic differences in antiseizure medications among people with epilepsy on Medicaid: a case of potential inequities. Neurol Clin Pract. 2023;13(1): e200101. https:\/\/doi.org\/10.1212\/CPJ.0000000000200101.","journal-title":"Neurol Clin Pract"},{"key":"924_CR86","doi-asserted-by":"publisher","DOI":"10.5070\/D329160221","author":"EL Bean","year":"2023","unstructured":"Bean EL, Lewis DJ, Weir MA, Micheletti RG. Delayed diagnosis of DRESS syndrome in a patient with skin of color. Dermatol Online J. 2023. https:\/\/doi.org\/10.5070\/D329160221.","journal-title":"Dermatol Online J"},{"issue":"3","key":"924_CR87","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1111\/ijd.16988","volume":"63","author":"JG Schneider","year":"2024","unstructured":"Schneider JG, Gallardo M, Fisher K, Kaffenberger BH, Korman AM. Increased mortality among African American patients with DRESS syndrome compared to white patients. Int J Dermatol. 2024;63(3):e80\u20131. https:\/\/doi.org\/10.1111\/ijd.16988.","journal-title":"Int J Dermatol"},{"issue":"12","key":"924_CR88","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/s41409-023-02109-x","volume":"58","author":"J Hong","year":"2023","unstructured":"Hong J, Fraebel J, Yang Y, Tkacyk E, Kitko C, Kim TK. Understanding and treatment of cutaneous graft-versus-host-disease. Bone Marrow Transpl. 2023;58(12):1298\u2013313. https:\/\/doi.org\/10.1038\/s41409-023-02109-x.","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"924_CR89","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40257-017-0306-9","volume":"19","author":"K Strong Rodrigues","year":"2018","unstructured":"Strong Rodrigues K, Oliveira-Ribeiro C, de Abreu Fiuza Gomes S, Knobler R. Cutaneous graft-versus-host disease: diagnosis and treatment. Am J Clin Dermatol. 2018;19(1):33\u201350. https:\/\/doi.org\/10.1007\/s40257-017-0306-9.","journal-title":"Am J Clin Dermatol"},{"issue":"10","key":"924_CR90","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1038\/s41409-022-01764-w","volume":"57","author":"SG Holtan","year":"2022","unstructured":"Holtan SG, et al. Disease progression, treatments, hospitalization, and clinical outcomes in acute GVHD: a multicenter chart review. Bone Marrow Transpl. 2022;57(10):1581\u20135. https:\/\/doi.org\/10.1038\/s41409-022-01764-w.","journal-title":"Bone Marrow Transpl"},{"issue":"4","key":"924_CR91","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/bmt.2012.187","volume":"48","author":"SE Lee","year":"2013","unstructured":"Lee SE, et al. Risk and prognostic factors for acute GVHD based on NIH consensus criteria. Bone Marrow Transpl. 2013;48(4):587\u201392. https:\/\/doi.org\/10.1038\/bmt.2012.187.","journal-title":"Bone Marrow Transpl"},{"issue":"11","key":"924_CR92","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1016\/j.bbmt.2014.06.031","volume":"20","author":"D Ion","year":"2014","unstructured":"Ion D, et al. Characterization of oral involvement in acute graft-versus-host disease. Biol Blood Marrow Transpl. 2014;20(11):1717\u201321. https:\/\/doi.org\/10.1016\/j.bbmt.2014.06.031.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"924_CR93","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.jaad.2010.07.042","volume":"65","author":"HJ Byun","year":"2011","unstructured":"Byun HJ, Yang JI, Kim BK, Cho KH. Clinical differentiation of acute cutaneous graft-versus-host disease from drug hypersensitivity reactions. J Am Acad Dermatol. 2011;65(4):726\u201332. https:\/\/doi.org\/10.1016\/j.jaad.2010.07.042.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"924_CR94","doi-asserted-by":"publisher","first-page":"e299","DOI":"10.1111\/ijd.15786","volume":"61","author":"C Calhoun","year":"2022","unstructured":"Calhoun C, Stallman E, Jaglowksi S, Kaffenberger BH. A retrospective study of acute graft-vs-host disease and its mimickers in the posttransplant period. Int J Dermatol. 2022;61(8):e299\u2013301. https:\/\/doi.org\/10.1111\/ijd.15786.","journal-title":"Int J Dermatol"},{"issue":"8","key":"924_CR95","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1111\/jcmm.12093","volume":"17","author":"L Qian","year":"2013","unstructured":"Qian L, Wu Z, Shen J. Advances in the treatment of acute graft-versus-host disease. J Cell Mol Med. 2013;17(8):966\u201375. https:\/\/doi.org\/10.1111\/jcmm.12093.","journal-title":"J Cell Mol Med"},{"issue":"9","key":"924_CR96","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1097\/00000478-199709000-00002","volume":"21","author":"S Kohler","year":"1997","unstructured":"Kohler S, Hendrickson MR, Chao NJ, Smoller BR. Value of skin biopsies in assessing prognosis and progression of acute graft-versus-host disease. Am J Surg Pathol. 1997;21(9):988\u201396. https:\/\/doi.org\/10.1097\/00000478-199709000-00002.","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"924_CR97","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.jaad.2004.02.019","volume":"51","author":"DE Marra","year":"2004","unstructured":"Marra DE, McKee PH, Nghiem P. Tissue eosinophils and the perils of using skin biopsy specimens to distinguish between drug hypersensitivity and cutaneous graft-versus-host disease. J Am Acad Dermatol. 2004;51(4):543\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2004.02.019.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"924_CR98","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1001\/archderm.1993.01680280043007","volume":"129","author":"DJ Bauer","year":"1993","unstructured":"Bauer DJ, Hood AF, Horn TD. Histologic comparison of autologous graft-vs-host reaction and cutaneous eruption of lymphocyte recovery. Arch Dermatol. 1993;129(7):855\u20138.","journal-title":"Arch Dermatol"},{"issue":"1","key":"924_CR99","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/cup.12427","volume":"42","author":"JS Lehman","year":"2015","unstructured":"Lehman JS, et al. Acute cutaneous graft-vs.-host disease compared to drug hypersensitivity reaction with vacuolar interface changes: a blinded study of microscopic and immunohistochemical features. J Cutan Pathol. 2015;42(1):39\u201345. https:\/\/doi.org\/10.1111\/cup.12427.","journal-title":"J Cutan Pathol"},{"issue":"1","key":"924_CR100","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/DAD.0b013e3181a85293","volume":"32","author":"J Weaver","year":"2010","unstructured":"Weaver J, Bergfeld WF. Quantitative analysis of eosinophils in acute graft-versus-host disease compared with drug hypersensitivity reactions. Am J Dermatopathol. 2010;32(1):31\u20134. https:\/\/doi.org\/10.1097\/DAD.0b013e3181a85293.","journal-title":"Am J Dermatopathol"},{"key":"924_CR101","doi-asserted-by":"crossref","unstructured":"Evans JB, Shearer SM, Zhao WJ, Jones D, Kaffenberger BH. Discordant molecular tests for acute graft-versus-host disease after liver transplant: FISHing for the proper diagnosis. Dermatol Online J. 2019;25(6).","DOI":"10.5070\/D3256044446"},{"issue":"6","key":"924_CR102","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13875","volume":"34","author":"A Grant","year":"2020","unstructured":"Grant A, Chapman LRM, Mitchell R, O\u2019Brien TA. Engraftment syndrome following hematopoietic stem cell transplant: a review of the literature. Clin Transplant. 2020;34(6): e13875. https:\/\/doi.org\/10.1111\/ctr.13875.","journal-title":"Clin Transplant"},{"issue":"11","key":"924_CR103","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1001\/archderm.1989.01670230054008","volume":"125","author":"TD Horn","year":"1989","unstructured":"Horn TD, Redd JV, Karp JE, Beschorner WE, Burke PJ, Hood AF. Cutaneous eruptions of lymphocyte recovery. Arch Dermatol. 1989;125(11):1512\u20137.","journal-title":"Arch Dermatol"},{"issue":"6","key":"924_CR104","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.jaad.2012.04.014","volume":"67","author":"F Drago","year":"2012","unstructured":"Drago F, Paolino S, Rebora A, Broccolo F, Cardo P, Parodi A. The challenge of diagnosing atypical exanthems: a clinico-laboratory study. J Am Acad Dermatol. 2012;67(6):1282\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2012.04.014.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"924_CR105","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1046\/j.1365-2133.2002.04826.x","volume":"147","author":"F Drago","year":"2002","unstructured":"Drago F, Rampini E, Rebora A. Atypical exanthems: morphology and laboratory investigations may lead to an aetiological diagnosis in about 70% of cases. Br J Dermatol. 2002;147(2):255\u201360. https:\/\/doi.org\/10.1046\/j.1365-2133.2002.04826.x.","journal-title":"Br J Dermatol"},{"issue":"2","key":"924_CR106","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/bjd.18166","volume":"182","author":"O Deschamps","year":"2020","unstructured":"Deschamps O, et al. Acute exanthemas: a prospective study of 98 adult patients with an emphasis on cytokinic and metagenomic investigation. Br J Dermatol. 2020;182(2):355\u201363. https:\/\/doi.org\/10.1111\/bjd.18166.","journal-title":"Br J Dermatol"},{"key":"924_CR107","doi-asserted-by":"publisher","first-page":"857519","DOI":"10.1155\/2013\/857519","volume":"2013","author":"A Tarhini","year":"2013","unstructured":"Tarhini A. Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica (Cairo). 2013;2013:857519. https:\/\/doi.org\/10.1155\/2013\/857519.","journal-title":"Scientifica (Cairo)"},{"issue":"5","key":"924_CR108","doi-asserted-by":"publisher","first-page":"405","DOI":"10.5301\/tj.5000625","volume":"103","author":"A Inno","year":"2017","unstructured":"Inno A, et al. Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity. Tumori. 2017;103(5):405\u201321. https:\/\/doi.org\/10.5301\/tj.5000625.","journal-title":"Tumori"},{"issue":"9948","key":"924_CR109","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","volume":"384","author":"C Robert","year":"2014","unstructured":"Robert C, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384(9948):1109\u201317. https:\/\/doi.org\/10.1016\/S0140-6736(14)60958-2.","journal-title":"Lancet"},{"issue":"4","key":"924_CR110","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1412082.","journal-title":"N Engl J Med"},{"issue":"1","key":"924_CR111","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1101a155","volume":"11","author":"Z Apalla","year":"2021","unstructured":"Apalla Z, et al. Cutaneous adverse events of immune checkpoint inhibitors: a literature review. Dermatol Pract Concept. 2021;11(1): e2021155. https:\/\/doi.org\/10.5826\/dpc.1101a155.","journal-title":"Dermatol Pract Concept"},{"issue":"6","key":"924_CR112","doi-asserted-by":"publisher","first-page":"489","DOI":"10.2217\/imt-2021-0244","volume":"14","author":"A Salloum","year":"2022","unstructured":"Salloum A, et al. Dermatological adverse events associated with immune checkpoint inhibitor-based combinations of anticancer therapies: a systematic review. Immunotherapy. 2022;14(6):489\u2013503. https:\/\/doi.org\/10.2217\/imt-2021-0244.","journal-title":"Immunotherapy"},{"issue":"4","key":"924_CR113","doi-asserted-by":"publisher","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","volume":"20","author":"JA Thompson","year":"2022","unstructured":"Thompson JA, et al. Management of immunotherapy-related toxicities, version 1.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(4):387\u2013405. https:\/\/doi.org\/10.6004\/jnccn.2022.0020.","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"924_CR114","doi-asserted-by":"publisher","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","volume":"18","author":"JA Thompson","year":"2020","unstructured":"Thompson JA, et al. NCCN Guidelines insights: management of immunotherapy-related toxicities, version 1.2020. J Natl Compr Canc Netw. 2020;18(3):230\u201341. https:\/\/doi.org\/10.6004\/jnccn.2020.0012.","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"924_CR115","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/CMR.0000000000000877","volume":"33","author":"S Ingen-Housz-Oro","year":"2023","unstructured":"Ingen-Housz-Oro S, et al. Drug reactions with eosinophilia and systemic symptoms induced by immune checkpoint inhibitors: an international cohort of 13 cases. Melanoma Res. 2023;33(2):155\u20138. https:\/\/doi.org\/10.1097\/CMR.0000000000000877.","journal-title":"Melanoma Res"},{"key":"924_CR116","unstructured":"N. C. C. Network. Management of immunotherapy-related toxicities. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/immunotherapy.pdf. Accessed 16 Sep 2024."},{"issue":"5","key":"924_CR117","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.jaad.2020.03.029","volume":"83","author":"GE Molina","year":"2020","unstructured":"Molina GE, Yu Z, Foreman RK, Reynolds KL, Chen ST. Generalized bullous mucocutaneous eruption mimicking Stevens-Johnson syndrome in the setting of immune checkpoint inhibition: a multicenter case series. J Am Acad Dermatol. 2020;83(5):1475\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2020.03.029.","journal-title":"J Am Acad Dermatol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00924-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-025-00924-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00924-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T07:56:57Z","timestamp":1747468617000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-025-00924-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,31]]},"references-count":117,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["924"],"URL":"https:\/\/doi.org\/10.1007\/s40257-025-00924-0","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,31]]},"assertion":[{"value":"15 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding Sources"}},{"value":"Not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"No relevant conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Patient consent was received for photo publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent to participate\/publish"}},{"value":"Data and material will be shared upon request to the corresponding author.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conceptualization: Ben Kaffenberger. Literature search: All authors. Writing\u2014original draft preparation: Allison Yan and Ben Kaffenberger. Writing\u2014review and editing: All authors. Supervision: Ben Kaffenberger. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}